GB stock · Healthcare sector · Drug Manufacturers—General
G
GSK plc
GSK
NYSE35.05
USD
-0.05
(-0.14%)
Market Open
12.99P/E
9Forward P/E
0.62P/E to S&P500
71.764BMarket CAP
1.75%Div Yield
Upcoming Earnings
1 Feb-6 Feb
Shares Short
3/15/23
3.84M
Short % of Float
- -
Short % of Shares Outs.
0.19%
% Held by Insiders
0.03%
% Held by Institutions
13.98%
Beta
0.27
PEG Ratio
1.82
52w. high/low
46.97/28.47
Avg. Daily Volume
3.86M
Return %
Stock
S&P 500
1 year
(34.33)
(9.05)
3 years
(26.26)
50.26
5 years
(28.10)
38.50
Scale: |
High
Low
68.30
38.77
54.34
33.94
53.91
40.20
57.31
45.35
59.62
52.10
67.50
54.60
70.91
51.61
61.35
46.55
56.98
46.50
55.67
43.15
52.95
43.61
59.46
47.00
60.31
39.29
55.69
41.91
58.71
28.46
36.83
33.33
Currency:
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
Revenue per share
10.29
11.64
13.99
13.94
13.62
13.45
13.72
11.96
12.38
14.35
15.45
15.68
17.06
17.13
17.05
14.57
Earnings per share
2.36
2.25
2.73
0.80
2.62
2.32
2.81
1.43
4.36
0.47
0.78
1.84
2.35
2.89
2.19
7.43
FCF per share
1.82
2.45
2.94
2.54
2.45
1.45
2.86
1.78
0.35
2.13
2.41
3.37
2.96
3.12
2.51
2.56
Dividends per share
1.27
1.44
1.52
1.57
1.69
1.94
1.90
2.00
2.00
2.49
2.00
2.00
2.00
2.00
2.00
1.72
CAPEX per share
0.97
0.99
0.92
0.80
0.66
0.77
0.88
0.91
0.98
1.21
1.13
0.91
1.09
1.12
1.46
1.12
Book Value per sh.
4.35
3.79
4.93
4.36
3.99
2.96
3.62
2.22
2.65
0.58
(0.03)
2.22
5.76
7.33
7.52
5.26
Comm.Shares outs.
2,210
2,092
2,028
2,036
2,011
1,965
1,932
1,923
1,932
1,944
1,954
1,966
1,979
1,990
2,001
2,013
Avg. annual P/E ratio
28.3
23.9
16.6
59.3
19.8
24.3
22.1
43.9
12.4
110.1
63.8
26.7
22.1
17.3
22.4
6.1
P/E to S&P500
1.6
1.1
0.2
2.9
1.2
1.6
1.3
2.4
0.6
5.0
2.7
1.1
0.9
0.5
0.7
0.3
Avg. annual div. yield
1.9%
2.7%
3.4%
3.3%
3.3%
3.4%
3.1%
3.2%
3.7%
4.8%
4.0%
4.1%
3.9%
4.0%
4.1%
3.8%
Revenue (m)
22,739
24,352
28,368
28,392
27,387
26,431
26,505
23,006
23,923
27,889
30,186
30,821
33,754
34,099
34,114
29,324
Operating margin
34.9%
29.3%
29.7%
13.3%
28.5%
28.0%
26.5%
15.6%
43.1%
9.3%
13.5%
17.8%
20.6%
22.8%
18.2%
21.9%
Depreciation (m)
1,023
1,231
1,562
1,679
1,423
1,445
1,414
1,484
1,630
1,774
1,922
1,856
2,334
2,351
2,377
2,298
Net profit (m)
5,219
4,712
5,531
1,634
5,261
4,565
5,436
2,756
8,422
912
1,532
3,623
4,645
5,749
4,385
14,956
Income tax rate
29.5%
29.2%
28.2%
41.3%
29.1%
29.1%
15.3%
4.6%
20.5%
45.2%
38.5%
15.7%
15.3%
8.3%
6.4%
12.6%
Net profit margin
23.0%
19.3%
19.5%
5.8%
19.2%
17.3%
20.5%
12.0%
35.2%
3.3%
5.1%
11.8%
13.8%
16.9%
12.9%
51.0%
Working capital (m)
3,284
7,252
5,452
3,242
1,157
(123)
1,550
1,383
3,170
(2,290)
(10,662)
(5,564)
(4,559)
(1,901)
(4,996)
(2,041)
Long-term debt (m)
7,074
15,231
14,786
14,809
12,203
14,671
15,456
15,841
15,324
14,661
14,264
20,271
23,590
23,425
20,572
17,035
Equity (m)
9,613
7,931
10,005
8,887
8,032
5,810
6,997
4,263
5,114
1,124
(68)
4,360
11,405
14,587
15,055
10,598
ROIC
27.3%
18.3%
20.4%
7.7%
23.3%
19.3%
22.1%
12.9%
24.8%
3.8%
8.5%
12.0%
11.3%
12.7%
10.5%
38.2%
Return on capital
25.7%
19.2%
20.3%
9.1%
20.6%
17.9%
17.4%
9.0%
22.8%
4.5%
6.9%
8.8%
8.9%
9.7%
7.6%
27.3%
Return on equity
54.3%
59.4%
55.3%
18.4%
65.5%
78.6%
77.7%
64.6%
164.7%
81.1%
(2,252.9)%
83.1%
40.7%
39.4%
29.1%
141.1%
Plowback ratio
47.4%
36.2%
45.5%
(73.0)%
37.6%
19.6%
34.6%
(35.7)%
53.7%
(356.7)%
(80.1)%
2.9%
25.0%
37.7%
21.5%
29.5%
Div.&Repurch./FCF
149.6%
129.7%
51.8%
60.9%
108.5%
207.7%
84.1%
117.1%
583.8%
116.6%
83.0%
58.2%
66.6%
63.7%
79.2%
66.9%
Forex (GBP/USD)
1.985
1.463
1.616
1.560
1.554
1.625
1.656
1.557
1.474
1.234
1.351
1.276
1.326
1.367
1.353
1.227
Capital Structure
31 Dec · 2022 | Q4
All numbers in millions
Total liabilities
$ 50,050
Total assets
$ 60,146
Long-term debt
$ 17,035
Cash and equiv.
$ 3,723
Goodwill
$ 7,046
Retained earnings
$ 4,363
Common stock
2,017
Enterprise Value
$ 85,076
Working Capital
Currency: USD, in millions
2020
2021
2022
Cash & Investments
6,170
4,135
7,877
Receivables
- -
- -
- -
Inventory
5,996
5,783
5,146
Other
8,081
6,738
5,377
Current assets
20,247
18,674
20,769
Acc. Payable
4,357
4,535
16,263
Debt due
3,725
3,601
3,952
Other
14,066
15,534
2,595
Current liabilities
22,148
23,670
22,810
Annual growth rates
(avg. rate of change)
1 year
5 years
10 years
Revenue
(14.04)%
(0.86)%
1.58%
Cash flow
2.47%
(5.57)%
48.23%
Earnings
241.07%
67.33%
60.10%
Dividends
(13.30)%
(2.87)%
0.00%
Book value
(29.60)%
40.77%
(727.98)%
Quarterly Revenue
Currency: USD, in millions
Year
1Q
2Q
3Q
4Q
Total
2020
9,090
7,624
8,646
8,739
34,099
2021
7,418
8,092
9,077
9,527
34,114
2022
9,780
6,929
7,829
7,376
31,914
Earnings per share
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2020
0.79
1.14
0.63
0.34
2.89
2021
0.54
0.70
0.58
0.37
2.19
2022
0.90
0.42
5.14
0.74
7.20
Quarterly dividends paid
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2020
0.47
0.57
0.48
0.48
2.00
2021
0.47
0.58
0.48
0.48
2.00
2022
0.47
0.57
0.35
0.32
1.72
Company Description
Sector:
Healthcare
Industry:
Drug Manufacturers—General
CEO:
Ms. Emma Natasha Walmsley
Full-time employees:
90,096
City:
Brentford
Address:
980 Great West Road
GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories. The company offers its consumer healthcare products in the form of nasal sprays, tablets, syrups, lozenges, gum and trans-dermal patches, caplets, infant syrup drops, liquid filled suspension, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams and non-medicated patches, lip balm, gummies, and soft chews. It has collaboration agreements with 23andMe; Lyell Immunopharma, Inc.; Novartis; Sanofi SA; Surface Oncology; Progentec Diagnostics, Inc.; Alector, Inc.; and CureVac AG., as well as strategic partnership with IDEAYA Biosciences, Inc. and Vir Biotechnology, Inc. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.
Recent News
· 31 Oct, 2022 · The Wall Street Journal
· 19 Jan, 2022 · The Wall Street Journal
· 15 Jan, 2022 · The Wall Street Journal
· 7 Dec, 2021 · The Wall Street Journal
· 2 Dec, 2021 · The Wall Street Journal
· 17 May, 2021 · The Wall Street Journal